Centre for Drug Safety
E535462
The Centre for Drug Safety is a specialized unit within the Norwegian Institute of Public Health that focuses on monitoring, researching, and improving the safe use of medicines.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Centre for Drug Safety canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5651934 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Centre for Drug Safety Context triple: [Norwegian Institute of Public Health, hasPart, Centre for Drug Safety]
-
A.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
B.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
C.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
D.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
E.
Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Centre for Drug Safety Target entity description: The Centre for Drug Safety is a specialized unit within the Norwegian Institute of Public Health that focuses on monitoring, researching, and improving the safe use of medicines.
-
A.
Center for Drug Evaluation and Research
The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
-
B.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
C.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
D.
Center for Biologics Evaluation and Research
The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
-
E.
Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
- F. None of above. chosen
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
public health unit
ⓘ
research centre ⓘ |
| affiliation | Norwegian Institute of Public Health ⓘ |
| collaboratesWith |
Norwegian Medicines Agency
ⓘ
healthcare providers in Norway ⓘ international drug safety networks ⓘ universities in Norway ⓘ |
| country | Norway ⓘ |
| employer |
clinical pharmacists
ⓘ
epidemiologists ⓘ pharmacologists ⓘ public health researchers ⓘ statisticians ⓘ |
| field |
drug safety
ⓘ
pharmacoepidemiology ⓘ pharmacovigilance ⓘ public health ⓘ |
| focusesOn |
drug utilization research
ⓘ
improving prescribing quality ⓘ medication safety in hospitals ⓘ medication safety in primary care ⓘ medication safety in special populations ⓘ monitoring of adverse drug reactions ⓘ post-marketing surveillance of medicines ⓘ rational use of medicines ⓘ risk–benefit assessment of medicines ⓘ safe use of medicines ⓘ |
| hasGoal |
improve patient safety related to medication use
ⓘ
provide evidence for regulatory decisions on medicines ⓘ reduce harm from medicines ⓘ support national medicines policy ⓘ |
| jurisdiction | Norway ⓘ |
| languageOfWork |
English
ⓘ
Norwegian ⓘ |
| location | Oslo ⓘ |
| operatedBy | Norwegian Institute of Public Health ⓘ |
| partOf | Norwegian Institute of Public Health ⓘ |
| researchActivity |
analysis of prescription databases
ⓘ
drug safety studies in pregnancy ⓘ drug safety studies in the elderly ⓘ population-based cohort studies on drug effects ⓘ signal detection for adverse drug reactions ⓘ |
| researchOutput |
reports for health authorities
ⓘ
scientific articles on drug safety ⓘ |
| sector | public sector ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Centre for Drug Safety Description of subject: The Centre for Drug Safety is a specialized unit within the Norwegian Institute of Public Health that focuses on monitoring, researching, and improving the safe use of medicines.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.